Thrombolytic therapy for submassive / intermediate risk Pulmonary Embolism Evidence and suggestions after PEITHO study
Terapia trombolítica en TEP submasivo/riesgo intermedio. Evidencias y sugerencias post estudio PEITHO
Author
Marin V, Arnaldo; Facultad de medicina uc
Gazmuri B, José Tomás; facultad de medicina uc
Andresen V, Max; facultad de medicina uc
Andresen, Max; Editor Asociado
Abstract
Therapy for submassive pulmonary embolism (intermediate risk), remains controversial. New evidence has appeared that may help us in the process of decision making. We review the relevant literature, outline prognostic factors, and discuss current recommendations and controversies regarding the available alternatives such as systemic and catheter-directed thrombolytic use. Therapy for submassive pulmonary embolism (intermediate risk), remains controversial. New evidence has appeared that may help us in the process of decision making. We review the relevant literature, outline prognostic factors, and discuss current recommendations and controversies regarding the available alternatives such as systemic and catheter-directed thrombolytic use.